Tumor-specific Dose Scheduling of Bimodal Radioimmunotherapy and Chemotherapy

Anticancer Research

Volumn 23, Issue 6 C, 2003, Pages 4613-4619

  Blumenthal, R D ^a,b   Leone, E ^a   Goldenberg, D M ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^b GARDEN STATE CANCER CENTER   (United States)

Author keywords

Chemotherapy; Radioimmunotherapy; Tumor specific dose

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DOXORUBICIN; EPITHELIAL GLYCOPROTEIN 1 ANTIBODY; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY RS 7; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; PROTEIN P53; TOPOTECAN; UNCLASSIFIED DRUG; YTTRIUM 90;

ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RADIOIMMUNOTHERAPY; RADIOSENSITIVITY;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; OVARIAN NEOPLASMS; RADIOIMMUNOTHERAPY; TUMOR CELLS, CULTURED; YTTRIUM RADIOISOTOPES;

EID: 0842333238     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Remmenga S, Colcher D, Gansow O, Pippen C and Raubitschek A: Continuous infusion chemotherapy as a radiation-enhancing agent for yttrium-90-radiolabeled monocloncal antibody therapy of a human tumor xenograft. Gyn Oncol 55: 115-122, 1994.
2. Tschmelitsch J, Barendswaard E, Williams C Jr, Yao TJ, Cohen AM, Old LJ and Welt S: Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil). Cancer Res 57: 2181-2186, 1997.
3. Kievit E, Pinedo HM, Schlueper HMM and Boven E: Addition of cisplatin improves efficacy of 131I-labeled monoclonal antibody 323/A3 in experimental human ovarian cancer. Int J Radiat Oncol Biol Phys 38: 419-428, 1997.
4. Roffler S, Chan J and Yeh M: Potentiation of radioimmunotherapy by inhibition of topoisomerase I. Cancer Res 54: 1276-1285, 1994.
5. Behr TM, Wulst E, Radetsky S, Blumenthal R, Dunn R, Gratz S, Rave-Frank M, Schmidberger H, Raue F and Becker W: Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunotherapy: Doxorubicin potentiates the therapeutic efficacy of radiolabeld antibodies in a radioresistant tumor type. Cancer Res 57: 5309-5319, 1997.
6. Desrues B, Lena H, Brichory F, Ramee MP, Toujas L, Delaval P and Dazord L: Monoclonal antibody Po66 uptake by human lung tumours implanted in nude mice: effect of co-administration with doxorubicin. Br J Cancer 72: 1076-1082, 1995.
7. Denardo SJ, Kukis D, Kroger L, O'Donnell R, Lamborn K, Miers L, Denardo DA, Meares C and Denardo GL: Synergy of taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: Efficacy and toxicity in breast cancer xenografts. Proc Natl Acad Sci USA 94: 4000-4004, 1997.
8. Katso RM, Manek SK, OB, Playford MP, Le Meuth V and Ganesan TS: Molecular approaches to diagnosis and management of ovarian cancer. Cancer Metastasis Rev 16: 81-107, 1997.
9. Mosmann, T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity. J Immunol Meth 65: 55-63, 1983.
10. Griffiths G, Govindan S, Sharkey R, Fisher D and Goldenberg D: 90Y-DOTA-hLL2: An agent for radioimmunotherapy of Non-Hodgkin's Lymphoma. J Nucl Med 44: 77-84, 2003.
11. McLeod H: Individualized cancer therapy: Molecular approaches to the prediction of tumor response. Expert Rev Anticancer Ther 2: 113-119, 2002.
12. Kandioler-Eckersberger D, Kappel S, Mittlbock M, Dekan G, Ludwig C, Janschek E, Pirker R, Wolner E and Eckersberger F: The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-basd neoadjuvant thrapy in stage III non-small cell lung cancer. J Thorac Cardiovasc Surg 117: 744-750, 1999.
13. Yu D, Liu B, Tan M, Li J, Wang SS and Hung MC: Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 13: 1359-1365, 1996.
14. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R et al: Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group [see comments]. J Clin Oncol 10: 1049-1056, 1992.
15. Germann UA: P-glycoprotein - A mediator of multidrug resisatnce in tumor cells. Eur J Cancer 32A: 927-944, 1996.
16. Loe D, Deeley R and Cole S: Biology of the multidrug resistance - associated protein, MRP. Eur J Cancer 32A: 945-957, 1996.
17. Vescio R, Conners K, Youngkin T, Bordin G, Robb J, Umbreit J and Hoffman R: Cancer biology for individualized therapy: correlation of growth fraction index in native-state histoculture with tumor grade and stage. Proc Natl Acad Sci USA 87: 691-695, 1990.
18. Kaser O, Castanno Y and Almendral A: Cancer of the endometrium stage I - standardized or individualized treatment? Eur J Obstet Gynecol Reprod Biol 18: 329-334, 1984.
19. Breidenbach M, Rein D, Mallmann P and Kurbacher C: Individualized long-term chemotherapy for recurrent ovarian cancer after failing high-dose treatment. Anticancer Drugs 13: 173-176, 2002.
20. Blumenthal R, Leone E, Goldenberg D, Rodriguez M and Modrak D: An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: effects of p53 expression. Int J Cancer submitted, 2003.
21. Weinberg M and Rauth A: 5-Fluorouracil and fractionated doses of radiation: studies with a murine squamouse cell carcinoma. Int J Radiat Oncol Biol Phys 13, 1987.
22. Byfield J, Barone R, Seagren S, Frankel S and Quinol L: Biweekly infused 5-fluorouracil and x-rays in advanced gastrointestinal cancer. Proc Am Soc Clin Oncol 18: 322-324, 1978.
23. Mason K, Hunter N, Milas M, Abbruzzese J and Milas L: Docetaxel enhances radioresponse in vivo. Clin Cancer Res 2: 2431-2438, 1997.
24. Tseng M and Safa A: In vitro drug screening and individualized treatment planning for cancer patients. Cancer Detect Prev 6: 371-379, 1983.
25. Shimizu E, Saijo N, Kanzawa F, Hoshi A, Eguchi K, Shinkai T, Tominaga K, Sasaki Y, Fujita J and Nomori H: Correlation between drug sensitivity determined by clonogenic cell assay and clinical effect of chemotherapy in patients with primary lung cancer. Gann 75: 1030-1035, 1990.
26. Yang S: Correlation of in vitro chemosensitivity and clinical responses to anticancer drugs in primary adenocarcinoma of the lung. J Formos Med Assoc 89: 214-219, 1990.
27. Bristow R and Hill R: Comparison between in vitro radiosensitivity and in vivo radioresponse in murn tumor cell lines. II: In vivo radioresponse following fractionated treatment and in vitro/in vivo correlations. Int J Radiat Oncol Biol Phys 18: 331-345, 1990.
28. Tonkin K, Kelland L and Steel G: A comparison of the in vivo and in vitro radiation response of three human cervix carcinomas. Radiother Oncol 16: 55-63, 1989.
29. Waldman T, Zhang Y, Dillehay L, Yu J, Kinzler K, Vogelstein B and Williams J: Cell-cycle arrest versus cell death in cancer therapy. Nature Med 3: 1034-1036, 1997.
30. Wouters B, Giaccia A, Denko N and Brown J: Loss of p21Waf1/Cip1 sensitizes tumors to radiation by an apoptosis-independent mechanism. Cancer Res 57: 4703-4706, 1997.
31. King DJ, Turner A, Farnsworth AP, Adair JR, Owens RJ, Pedley RB, Baldock D, Proudfoot KA, Lawson AD, Beeley NR et al: Improved tumor targeting with chemically cross-linked recombinant antibody fragments. Cancer Res 54: 6176-6185, 1994.
32. Hu S, Shively L, Raubitschek A, Sherman M, Williams LE, Wong JY, Shively JE and Wu AM: Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 56: 3055-3061, 1996.
33. Behr T, Memtsoudis S, Sharkey R, Blumenthal R, Dunn R, Gratz S, Wieland W, Nebedahl K, Schmidbeger H, Goldenberg D and Becker W: Experimental studies on the role of antibody fragments in cancer radioimmunotheapy: influence of radiations dose and dose rate on toxicity and anti-tumor efficacy. Int J Cancer 77: 787-795, 1998.
34. Behr T, Blumenthal R, Memtsoudis S, Shakey R, Gratz S, Becker W and Goldenberg D: Cure of metastatic human colonic cancer in mice with radiolabeled monoclonal antibody fragments. Clin Cancer Res 6: 4900-4907, 2000.